|
December 10, 2007 - INNOVIVE Pharmaceuticals Presents Phase I Data on INNO-406 for Treatment of Gleevec-resistant or Intolerant Chronic Myelogenous Leukemia at ASH
December 8, 2007 - INNOVIVE Pharmaceuticals Presents Preliminary Data at ASH Showing INNO-305 Elicits Immune Response in Patients with Myeloid and Thoracic Neoplasms
December 5, 2007 - Data from INNOVIVE Pharmaceuticals’ Oncology Drug Programs to be Presented at the American Society of Hematology 49th Annual Meeting
November 15, 2007 - INNOVIVE Pharmaceuticals Initiates Pivotal Phase II Clinical Trial with Tamibarotene
November 14, 2007 - INNOVIVE Pharmaceuticals Announces Third Quarter 2007
November 1, 2007 - INNOVIVE Pharmaceuticals toPresent at the Rodman & Renshaw Acumen BioFin 9th Annual Healthcare Conference
October 19, 2007 - INNOVIVE Pharmaceuticals to Present at the Paramount BioSciences Annual Healthcare Conference
October 15, 2007 - INNOVIVE Pharmaceuticals Announces Receipt of FDA Orphan Drug Designation for Tamibarotene for the Treatment of Acute Promyelocytic Leukemia
October 5, 2007 - INNOVIVE Pharmaceuticals to Present at the BIO InvestorForum
September 11, 2007 - INNOVIVE Pharmaceuticals to Present at the Merriman Curhan Ford Investor Summit
September 10, 2007 - INNOVIVE Pharmaceuticals Acquires Exclusive Rights to Develop and Commercialize Tamibarotene in Europe
August 3, 2007 - INNOVIVE Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for Pivotal Phase II Clinical Trial with Tamibarotene in Refractory Acute Promyelocytic Leukemia
June 7, 2007 - INNOVIVE Pharmaceuticals Receives FDA Fast Track Designation for Tamibarotene for the Treatment of Acute Promyelocytic Leukemia
June 2, 2007 - INNOVIVE Pharmaceuticals Presents Additional Phase I Data on INNO-406 for Treatment of Gleevec-resistant or Intolerant Chronic Myelogenous Leukemia at the American Society of Clinical Oncology Annual Meeting
May 30, 2007 - INNOVIVE Pharmaceuticals to present Interim Data from Phase I Study of INNO-406 at the American Society of Clinical Oncology Annual Meeting
May 16, 2007 - INNOVIVE Pharmaceuticals to Present at the 18th Annual Wall Street Analyst Forum
May 15, 2007 - INNOVIVE Pharmaceuticals Pharmaceuticals Announces First Quarter 2007
April 30, 2007 - INNOVIVE Pharmaceuticals Appoints Phil Frost, M.D., Ph.D. to its Board of Directors
April 25, 2007 - INNOVIVE Pharmaceuticals Closes $15 Million Equity Financing
April 18, 2007 - INNOVIVE Pharmaceuticals Announces Preclinical Data from INNO-206 Oncology Program
April 16, 2007 - INNOVIVE Pharmaceuticals Announces Interim Phase I Data on INNO-406 for the Treatment of Gleevec-resistant or Intolerant Chronic Myelogenous Leukemia
April 12, 2007 - INNOVIVE Pharmaceuticals Announces Additional Data Presentations at American Association for Cancer Research Annual Meeting
April 10, 2007 - INNOVIVE Pharmaceuticals to Present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
April 10, 2007 - INNOVIVE Pharmaceuticals Announces Data from Oncology Drug Programs to be Presented at American Association for Cancer Research Annual Meeting
March 21, 2007 - INNOVIVE Pharmaceuticals, Inc. (OTCBB: IVPH) today announced corporate highlights and financial results for the year ended December 31, 2006
February 16, 2007 - INNOVIVE Pharmaceuticals Appoints Angelo De Caro to its Board of Directors and Audit Committee
February 7, 2007 - INNOVIVE Pharmaceuticals to Present at the BIO CEO & Investor Conference
January 4, 2007 - INNOVIVE Pharmaceuticals Announces Receipt of FDA Orphan Drug Designation for INNO-406 for the Treatment of Chronic Myelogenous Leukemia
2006 Archive
2005 Archive
2004 Archive
If you are a journalist interested in reporting on cancer treatments involving any of the technologies being developed by INNOVIVE Pharmaceuticals, please contact Rachel Lipsitz.
Email: rlipsitz@pnlifesciences.com
Phone: 619-849-5378
|
